Updated September 2026Annual plan, billed up frontTrimi Health review
Both monthly figures here are an annual plan divided by twelve, charged in a single payment at the start.
The verdict
Trimi Health advertises $99 a month for compounded semaglutide and $125 for compounded tirzepatide. Both are annual plans billed at once, at $1,188 and $1,500, or split through a buy-now-pay-later provider.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- States
- 50
- From
- $99/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
Trimi Health sells compounded semaglutide and compounded tirzepatide by injection, shipping to all fifty states. The figures on its page are the advertised headline rates, and both describe a twelve-month plan. Semaglutide is billed as $1,188 for the year and tirzepatide as $1,500. Affirm, Klarna and Afterpay are offered as ways to spread that charge.
Who writes the prescription, and what do they see?
Care is arranged remotely and a prescription is required before the first vial ships. The page prices a twelve-month plan rather than a course of clinician contact. How often a patient is seen across that year, and by whom, is not published. The annual charge is described as the cost of the plan, not as a fee for a visit.
Care is arranged remotely and the plan runs for a year from the first payment. The rate is stated as flat across doses, so a titration does not move the figure. That matters most between month one and month four, when the dose usually rises. Whether a plan can be ended early, and on what terms, is not published.
What happens when the dose goes up?
The rate is stated as flat across doses, so an escalation leaves the figure alone. That claim is worth more here than at a month-to-month seller, because the whole year is already paid for. A reader who reaches a maintenance dose in month four is still on the rate agreed in month one. What happens if a clinician moves a patient to the other molecule mid-plan is not stated.
What the price includes
The monthly framing and the billing are different things here, and the second one is what a card is charged. $99 a month reads like a month-to-month rate and is an annual commitment of $1,188. The tirzepatide plan is $1,500, which works out at $125 across twelve months. A buy-now-pay-later arrangement spreads the payment without shortening the term.
What it claims, and what it cites
Both products are compounded, which means a pharmacy prepares them rather than a manufacturer. A compounded preparation is not FDA-approved and is not reviewed before it is dispensed. The published trial evidence for these molecules used the approved products at the doses on their labels. Whether a compounded vial matches those products in content or purity is not measured.
Where it holds up, and where it does not
- Strength: Rate stated as flat across doses
- Strength: Annual cost published as a total
- Strength: Ships to all fifty states
- Limitation: Monthly figure is an annual plan
- Limitation: Full year is charged at the start
- Limitation: Financing spreads payment, not the term
What the evidence says about this kind of treatment
The assessment above is about Trimi Health. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who can pay a year at once, or finance it, and wants the monthly figure to stop moving as the dose rises.
- Wrong for
- A reader who wants to stop after a month or two, because the plan behind both figures is a twelve-month one charged up front.
How Trimi Health compares
| Seller | Who it suits | Go |
|---|---|---|
| Lean Meds | A reader deciding between paying month to month and committing a year up front, because both rungs are published side by side. | See Lean Meds → |
| Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | See Collective → |
| Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | See Alloy → |
More GLP-1 telehealth sellers reviews: Apex MDAVARA RxBayan HealthBioGlow HealthDoctorAdamEmbody
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- Is $99 a month what the card is charged?
- No. The plan is annual and the charge is $1,188 at the start, which is $99 across twelve months. Affirm, Klarna and Afterpay are offered to spread that payment.
- Does the tirzepatide plan work the same way?
- It does. The advertised $125 a month is a $1,500 annual plan billed on the same terms as the semaglutide one.
- Will the price change as the dose goes up?
- Trimi Health states a flat rate across doses. The figure therefore holds through the escalation, which is where many sellers in this category reprice.
- Is Trimi Health expensive compared with other GLP-1 telehealth sellers?
- Trimi Health publishes a starting figure of $99/mo. Across the 32 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $299 with a median of $139, which puts Trimi Health below the median, toward the cheaper end. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.